Ratings Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Real-time Estimate Cboe BZX Other stock markets 02:36:10 2024-09-16 pm EDT			5-day change	1st Jan Change
355.28 ^USD	+1.03%		+4.69%	+15.91%

Aug. 26	Medpace Holdings Insider Sold Shares Worth $3,175,463, According to a Recent SEC Filing	MT
Aug. 15	Skanska Builds New Office Building in Cincinnati, Ohio, USA, for USD 164 Million, About SEK 1.7 Billion	CI

Summary: Medpace Holdings, Inc.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Highlights: Medpace Holdings, Inc.

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 47% by 2026.
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Medpace Holdings, Inc.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.35 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 4.75 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
Revenue estimates are regularly revised downwards for the current and coming years.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings Chart: Medpace Holdings, Inc.

Source: Surperformance

ESG chart: Medpace Holdings, Inc.

Source: Refinitiv

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
MEDPACE HOLDINGS, INC.		10.88B
LONZA GROUP AG		47.27B
IQVIA HOLDINGS INC.		43.52B
ALNYLAM PHARMACEUTICALS, INC.	-	34.06B
CELLTRION, INC.		30.33B
MODERNA, INC.	-	26.25B
ICON PUBLIC LIMITED COMPANY		24.84B
UNITED THERAPEUTICS CORPORATION		15.09B
BIO-TECHNE CORPORATION		11.85B
QIAGEN N.V.		10.3B
Average		25.44B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

C+

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes